Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Avci
Fikri Avci, Boston, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20120064108 | GLYCOCONJUGATE VACCINES - Glycoconjugate vaccines and methods of preparing and using the same are described. | 03-15-2012 |
Fikri Y. Avci, Boston, MA US
| Patent application number | Description | Published |
|---|---|---|
| 20090197308 | Enzymatic synthesis of sulfated polysaccharides - A method of sulfating a polysaccharide is provided. The method can include providing a reaction mixture comprising at least one O-sulfotransferase (OST) enzyme and 3′-phosphoadenosine 5′-phosphosulfate (PAPS); incubating a polysaccharide substrate with the reaction mixture, wherein production of the sulfated polysaccharide from the polysaccharide substrate is catalyzed by the OST enzyme with a conversion of the PAPS to adenosine 3′,5′-diphosphate (PAP); and providing a reaction condition which modifies PAP to reduce an inhibitory effect of PAP on the polysaccharide sulfation. | 08-06-2009 |
Oktay Avci, Izmir TR
| Patent application number | Description | Published |
|---|---|---|
| 20090286822 | Treatment of psoriasis and of other skin disorders associated with inhibition of differentiation of epidermal cells - This invention concerns the use of cyclopamine, a naturally occurring steroidal alkaloid known for over thirty years, for the treatment of psoriasis and achievement of rapid clearance of the psoriatic skin lesions together with the reversion of the histopathological signs of disease to normalcy with no detectable side effects. The cyclopamine-induced clearance of psoriatic lesions from the skin of patients is associated with the causation of cellular differentiation in lesional epidermis and with the rapid disappearance of CD4(+) lymphocytes and other inflammatory cells from lesional skin. Therapeutic compositions comprising of cyclopamine and a corticosteroid and/or the pre-treatment of lesions with a corticosteroid provide significantly further increased therapeutic effectiveness over the use of cyclopamine alone or a corticosteroid alone. | 11-19-2009 |
| 20100048725 | USE OF CYCLOPAMINE IN THE TREATMENT OF BASAL CELL CARCINOMA AND OTHER TUMORS - This invention concerns the use of cyclopamine in vivo on basal cell carcinomas (BCC's) to achieve therapeutic effect by causing differentiation of the tumor cells and, at the same time, apoptotic death and removal of these tumor cells while preserving the normal tissue cells, including the undifferentiated cells of the normal epidermal basal layer and hair follicles. Causation of apoptosis by cyclopamine is by a non-genotoxic mechanism and thus unlike the radiation therapy and most of the currently used cancer chemotherapeutics which act by causing DNA-damage. These novel effects, previously unachieved by a cancer chemotherapeutic, make the use of cyclopamine highly desirable in cancer therapy, in the treatment of BCC's and other tumors that use the hedgehog/smoothened signal transduction pathway for proliferation and prevention of apoptosis. | 02-25-2010 |
| 20110104254 | Medicament for treatment of tumors wherein hedgehog/smoothened signaling is employed for inhibition of apoptosis of the tumor cells - This invention concerns the use of cyclopamine in vivo on basal cell carcinomas (BCC's) to achieve therapeutic effect by causing differentiation of the tumor cells and, at the same time, apoptotic death and removal of these tumor cells while preserving the normal tissue cells, including the undifferentiated cells of the normal epidermal basal layer and hair follicles. Causation of apoptosis by cyclopamine is by a non-genotoxic mechanism and thus unlike the radiation therapy and most of the currently used cancer chemotherapeutics which act by causing DNA-damage. These novel effects, previously unachieved by a cancer chemotherapeutic, make the use of cyclopamine highly desirable in cancer therapy, in the treatment of BCC's and other tumors that use the hedgehog/smoothened signal transduction pathway for proliferation and prevention of apoptosis. | 05-05-2011 |
Recep Avci, Bozeman, MT US
| Patent application number | Description | Published |
|---|---|---|
| 20100206326 | METHODS FOR REMOVING CONTAMINANT MATTER FROM A POROUS MATERIAL - Methods of removing contaminant matter from porous materials include applying a polymer material to a contaminated surface, irradiating the contaminated surface to cause redistribution of contaminant matter, and removing at least a portion of the polymer material from the surface. Systems for decontaminating a contaminated structure comprising porous material include a radiation device configured to emit electromagnetic radiation toward a surface of a structure, and at least one spray device configured to apply a capture material onto the surface of the structure. Polymer materials that can be used in such methods and systems include polyphosphazine-based polymer materials having polyphosphazine backbone segments and side chain groups that include selected functional groups. The selected functional groups may include iminos, oximes, carboxylates, sulfonates, β-diketones, phosphine sulfides, phosphates, phosphites, phosphonates, phosphinates, phosphine oxides, monothio phosphinic acids, and dithio phosphinic acids. | 08-19-2010 |
| 20100206345 | SYSTEMS AND STRIPPABLE COATINGS FOR DECONTAMINATING STRUCTURES THAT INCLUDE POROUS MATERIAL - Methods of removing contaminant matter from porous materials include applying a polymer material to a contaminated surface, irradiating the contaminated surface to cause redistribution of contaminant matter, and removing at least a portion of the polymer material from the surface. Systems for decontaminating a contaminated structure comprising porous material include a radiation device configured to emit electromagnetic radiation toward a surface of a structure, and at least one spray device configured to apply a capture material onto the surface of the structure. Polymer materials that can be used in such methods and systems include polyphosphazine-based polymer materials having polyphosphazine backbone segments and side chain groups that include selected functional groups. The selected functional groups may include iminos, oximes, carboxylates, sulfonates, β-diketones, phosphine sulfides, phosphates, phosphites, phosphonates, phosphinates, phosphine oxides, monothio phosphinic acids, and dithio phosphinic acids. | 08-19-2010 |
Recep Avci, Istanbul TR
| Patent application number | Description | Published |
|---|---|---|
| 20110098315 | PHARMACEUTICAL COMPOSITIONS OF ROSUVASTATIN CALCIUM - This invention is related to pharmaceutical compositions of rosuvastatin or pharmaceutically acceptable salts thereof especially calcium salt with sodium carbonate anhydrous which has effects on dissoltion profiles in 0.1 N HCI medium provided that using of sodium carbonate anhydrous should be presence in the range of from about 0.5% to about 2% by weight. | 04-28-2011 |
| 20110198774 | USING OF ORGANIC SOLVENTS IN WET GRANULATION OF MOXIFLOXACIN - This invention encompasses to obtain non-convertible solid pharmaceutical formulations of moxifloxacin anhydrous by using of wet granulation with an organic solvent or mixtures of organic solvents. | 08-18-2011 |
| 20110256221 | PHARMACEUTICAL FORMULATIONS OF OLMESARTAN - This invention is related to pharmaceutical compositions, which have good flowability properties, comprising olmesartan medoxomil or combination of olmesartan medoxomil and hydrochlorothiazide and a lubricant or mixtures of lubricants and a pharmaceutically acceptable excipient or excipients. | 10-20-2011 |
Sel Avci, Kendall Park, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090183649 | Compositions Useful to Provide Improved Rheology and Mist Control to Ink Formulations and Ink Formulations Containing Such Compositions - The invention is ink formulations that show improved rheological and antimisting properties. The invention is particularly useful in lithographic inks including heatset, sheetfed and UV curable lithographic inks. The invention also includes novel additive that enable the preparation of inks with required viscosities that are needed to perform on high-speed printing presses with improved performance. The additive is based on reaction products of polyamines and carboxylic acids with two or more carboxylic moieties mixed or combined with tridecyl alcohol. In addition, the inventive additive is in the form of liquid and it is pourable and pumpable for ink manufacturing processes. | 07-23-2009 |
Selcuk Avci, Kendall Park, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20090151601 | LOW VOC WATERBASED COATINGS WITH EFFLORESCENCE RESISTANCE - A method to improve an efflorescence resistance of film forming compositions. The method comprises the step of adding a coalescent aid comprising a fatty acid ester to the film forming composition, the fatty acid ester has a formula of RCOOX wherein R is a hydrocarbyl having one or more aliphatic carbon-carbon double bonds, and X is selected from a group consisting of: a saturated hydrocarbyl, a hydrocarbyl having one or more aliphatic carbon-carbon double bonds and a substituted hydrocarbyl. These non volatile organic fatty acid ester based coalescents impart superior efflorescence resistance and resistance to color change to film forming compositions, including latex paints, versus conventional, VOC coalescent solvent. | 06-18-2009 |
Uygar E. Avci, Beaverton, OR US
| Patent application number | Description | Published |
|---|---|---|
| 20090003050 | FLOATING BODY MEMORY ARRAY - Provided herein are embodiments of layouts for applying impact ionization potentials across the channel of a selected floating body cell in an array without having to impose the potential on other unselected cells. | 01-01-2009 |
| 20100165772 | Self aligned back-gate for floating body cell memory erase - In some embodiments all cells within a word-line of a floating body cell memory are erased. A back-gate of the floating body cell memory is self-aligned with the word line, and the erasing is performed using a back-gate bias. Other embodiments are described and claimed. | 07-01-2010 |